Journal of Bioterrorism and Biodefense

Development of new purified vero cell rabies vaccine (Rabivax-S) at the Serum Institute of India Pvt.Ltd.

Ashish Sahai

B a :

Serum Institute of India Pvt. Ltd, India

Abstract

Introduction: TRabies is a 100% vaccine-preventable disease. Rabies disease still causes human deaths in the endemic areas in Asia and Africa. A cheap, rabies vaccine for humans that could be used in mass vaccination campaigns would be a valuable weapon against rabies. Serum institute of India Pvt. Ltd. has developed a new puri, ed vero cell inactivated and l^ophili:ed rabies vaccine (Rabivax-S) which is now a WHO prequali, ed rabies vaccine.

Methodology, Theoretical Orientation & Findings: Large scale production of Vero ATCC CCL81 cells were seeded in cell cube s^stem. Then cells are infected with Pitman Moore (PM 3218) strain of rabies virus. After 48-72 hrs, infected cells are washed. The multiple harvests are collected from one cell cube s[^]stem and clari, ed b[^] , Itration. Clari, ed harvest is concentrated using tangential 'ow , Itration s^stem. Inactivation of rabies virus is done

bags. A number of puri, ed rabies antigen bags are blended to achieve set antigen content in , nal bulk. The liquid vaccine is , lled in 1 ml USP t pe 1 clear and tubular vial and I ophili:ed. With the I ophili:ed vial of rabies vaccine 1.0 ml of sterile water for injection is supplied as a diluents.

Conclusion & Signifcance: Stud[^] gives well developed new puri, ed vero cell rabies vaccine (Rabivax-S), following all the GMP requirements. Animal stud^ has demonstrated no toxicit^ issue. We evaluated its safet^, toxicit[^] and immunogenicit[^] in post-exposure proph[^]laxis in clinical trials b[^] IM and ID routes. This vaccine is good option among the available modern WHO preguali, ed rabies vaccine. Filling, I^ophili: ation and packaging of , nal product.

#